The global acute myeloid leukaemia market reached $1bn in 2017 and is estimated to reach $2.8bn by 2022. In 2017, the chemotherapy segment held 69% of the global acute myeloid leukaemia market.
How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 135-page report you will receive 92 charts– all unavailable elsewhere.
The 135-page report provides clear detailed insight into the acute myeloid leukaemia market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.
Report Scope
• Global Acute Myeloid Leukaemia Market from 2018-2028
• Forecast of the Global Acute Myeloid Leukaemia market by Treatment Type and Product Type:
• Chemotherapy: Cytarabine, Daunorubicin, Others
• Targeted Therapy: Midostaurin, Enasidenib, Others
• This report provides individual revenue forecasts to 2028 for these regional and national markets:
• North America: US, Canada, and Mexico
• Europe: Germany, France, United Kingdom, Italy, Spain, Russia, and rest of Europe
• Asia-Pacific: Japan, China, Australia, South Korea, India, and rest of Asia-Pacific
• LAMEA: Brazil, Saudi Arabia, Republic of South Africa, Turkey, and rest of LAMEA
• Our study discusses the selected leading companies that are the major players in the acute myeloid leukaemia market:
• Bristol-Myers Squibb Company
• Celgene
• Clavis Pharma ASA
• Daiichi Sankyo
• Eisai
• GSK
• Novartis
• Roche
• Sunesis Pharmaceuticals
• Teva
• This report discusses factors that drive and restrain the acute myeloid leukaemia market. This report also discusses the opportunities that can be tapped in this market.
• This report also discusses several new agents that are in development for the treatment of acute myeloid leukaemia.
Visiongain’s study is intended for anyone requiring commercial analyses for the acute myeloid leukaemia market. You find data, trends and predictions.
Buy our report today Acute Myeloid Leukaemia Market Analysis : Chemotherapy, Targeted Therapy, Cytarabine, Daunorubicin, Midostaurin, Enasidenib.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
1. Report Overview
1.1 Global Acute Myeloid Leukaemia Market Overview
1.2 Market Definition & Scope
1.3 Overview of Findings
1.4 Structure of the Report1.5 Key Questions Answered by This Analytical Report
1.6 How This Report Delivers
1.7 Who is This Report For?
1.8 Methodology
1.8.1 Primary Research
1.8.2 Secondary Research
1.8.3 Market Evaluation & Forecasting Methodology
1.9 Frequently Asked Questions (FAQ)
1.10 Associated Visiongain Reports
1.11 About Visiongain
2. Introduction to Acute Myeloid Leukaemia
2.1 Market definition and scope
2.2 Myeloid Leukaemia: An Overview
2.2.1 Phases of treatment
2.2.2 Medication Overview
2.3 The Need of Acute Myeloid Therapeutics
3. Acute Myeloid Leukaemia Market: World Market 2018-2028
3.1 The World Acute Myeloid Leukaemia Market Overview and Segmentation, 2017
3.2 World Acute Myeloid Leukaemia Market: Sales Forecast 2017-2028
3.3 How Will Segments Market Shares Change to 2028?
4. Global Acute Myeloid Leukaemia Market by Treatment Type 2018-2028
4.1 Market Size and Forecast 2017-2028
4.2 Chemotherapy
4.2.1 Chemotherapy Market Size and Forecast 2017-2028
4.2.2 Cytarabine Market Size 2017-2028
4.2.3 Daunorubicin Market Size 2017-2028
4.2.4 Other Chemotherapy Products Market Size 2017-2028
4.3 Targeted Therapy
4.3.1 Targeted Therapy Market Size and Forecast 2017-2028
4.3.2 Midostaurin Market Size and Forecasts 2017-2028
4.3.3 Enasidenib Market Size and Forecasts 2017-2028
4.3.4 Other Targeted Therapy Products Market Forecasts 2017-2028
5. Global Acute Myeloid Leukaemia Market by Region 2018-2028
5.1 Global Acute Myeloid Leukaemia Market by Region: Revenue Forecast, 2018-2028
5.2 North America AML Market Forecast 2017-2028
5.2.1 North America Acute Myeloid Leukaemia Market by Country: Revenue Forecast, 2018-2028
5.2.1.1 US Acute Myeloid Leukaemia Market: Revenue Forecast, 2018-2028
5.2.1.2 Canada Acute Myeloid Leukaemia Market: Revenue Forecast, 2018-2028
5.2.1.3 Mexico Acute Myeloid Leukaemia Market: Revenue Forecast, 2018-2028
5.3 Europe Acute Myeloid Leukaemia Market Forecast 2017-2028
5.3.1 Europe Acute Myeloid Leukaemia Market by Country: Revenue Forecast, 2018-2028
5.3.1.1 Germany Acute Myeloid Leukaemia Market: Revenue Forecast, 2018-2028
5.3.1.2 France Acute Myeloid Leukaemia Market: Revenue Forecast, 2018-2028
5.3.1.3 United Kingdom Acute Myeloid Leukaemia Market: Revenue Forecast, 2018-2028
5.3.1.4 Italy Acute Myeloid Leukaemia Market: Revenue Forecast, 2018-2028
5.3.1.5 Spain Acute Myeloid Leukaemia Market: Revenue Forecast, 2018-2028
5.3.1.6 Russia Acute Myeloid Leukaemia Market: Revenue Forecast, 2018-2028
5.3.1.7 Rest of Europe Acute Myeloid Leukaemia Market: Revenue Forecast, 2018-2028
5.4 Asia-Pacific Acute Myeloid Market Forecasts 2018-2028
5.4.1 Asia-Pacific Acute Myeloid Leukaemia Market by Country: Revenue Forecast, 2018-2028
5.4.1.1 Japan Acute Myeloid Leukaemia Market: Revenue Forecast, 2018-2028
5.4.1.2 China Acute Myeloid Leukaemia Market, Revenue Forecast, 2018-2028
5.4.1.3 Australia Acute Myeloid Leukaemia Market: Revenue Forecast, 2018-2028
5.4.1.4 South Korea Acute Myeloid Leukaemia Market: Revenue Forecast, 2018-2028
5.4.1.5 India Acute Myeloid Leukaemia Market: Revenue Forecast, 2018-2028
5.4.2 Rest of Asia-Pacific Acute myeloid leukaemia Market, Revenue Forecast, 2018-2028
5.5 LAMEA Acute Myeloid Market Forecasts 2018-2028
5.5.1 LAMEA Acute Myeloid Leukaemia Market by Country: Revenue Forecast, 2018-2028
5.5.1.1 Brazil Acute Myeloid Leukaemia Market: Revenue Forecast, 2018-2028
5.5.1.2 Saudi Arabia Acute Myeloid Leukaemia Market: Revenue Forecast, 2018-2028
5.5.1.3 Republic of South Africa Acute Myeloid Leukaemia Market: Revenue Forecast, 2018-2028
5.5.1.4 Rest of LAMEA Acute Myeloid Leukaemia Market: Revenue Forecast, 2018-2028
6. Leading Companies in Acute Myeloid Leukaemia Market
6.1 Daiichi Sankyo
6.1.1 Company Overview
6.1.2 Financial Highlights
6.1.3 Recent Strategic Developments
6.2 Celgene Corporation
6.2.1 Company Overview
6.2.2 Operating Segments
6.2.3 Financial Highlights
6.2.4 Recent Strategic Developments
6.3 TEVA Pharmaceutical Industries Limited
6.3.1 Company Overview
6.3.2 Operating Segments
6.3.3 Financial Highlights
6.3.4 Recent Strategic Developments
6.4 Eisai Co., Ltd.
6.4.1 Company Overview
6.4.2 Operating Segments
6.4.3 Financial Highlights
6.5 Novartis AG
6.5.1 Company Overview
6.5.2 Operating Segments
6.5.3 Financial Highlights
6.5.4 Recent Strategic Developments
6.6 GlaxoSmithKline plc
6.6.1 Company Overview
6.6.2 Operating Segments
6.6.3 Financial Highlights
6.7 Sunesis Pharmaceuticals, Inc.
6.7.1 Company Overview
6.7.2 Operating Segments
6.7.3 Financial Highlights
6.8 Clavis Pharma ASA
6.8.1 Company Overview
6.9 F. Hoffmann-La Roche Ltd.
6.9.1 Company Overview
6.9.2 Operating Segments
6.9.3 Financial Highlights
6.9.4 Recent Strategic Developments
6.10 Bristol-Myers Squibb Company
6.10.1 Company Overview
6.10.2 Operating Segments
6.10.3 Financial Highlights
7. Acute Myeloid Leukaemia Market: Qualitative Analysis
7.1 Market Dynamics
7.1.1 Drivers
7.1.1.1 Rise in Cases of Chronic Diseases
7.1.1.2 Research for Innovative Therapeutics
7.1.1.3 Growth in Aging Population Base Worldwide
7.1.2 Restraints
7.1.2.1 Adverse Effects of the Treatment
7.1.3 Opportunities
7.1.3.1 Unmet oncological therapeutics demand.
7.1.3.2 Untapped opportunities in the developing nations
8. Pipeline and clinical trials analysis
8.1 Pipeline analysis
8.1.1 Vosaroxin (Sunesis Pharmaceuticals)
8.1.2 CPX-351 (Celator Pharmaceuticals, Inc.)
8.1.3 Sapacitabine (Cyclacel)
8.1.4 SGI-110 (Astex)
8.2 Small-Molecule Targeted Therapies
8.2.1 Volasertib (Boehringer Ingelheim)
8.3 Isocitrate Dehydrogenase Inhibitors
8.3.1 ABT-199s (AbbVie, Roche)
8.3.2 FLT3 Inhibitors
8.3.3 Sorafenib (Bayer, Onyx Pharmaceuticals)
8.3.4 Midostaurin (Novartis)
8.3.5 Quizartinib (Daiichi Sankyo)
8.4 Monoclonal Antibodies
8.4.1 SGN-33A (Seattle Genetics)
8.4.2 AMG-330 (Amgen)
8.5 Clinical trials
9. Conclusion
Appendices
Associated Visiongain Reports
Visiongain Report Sales Order Form
About Visiongain
Visiongain Report evaluation form
List of Tables
Table 4.1 Global Acute Myeloid Leukaemia Market by Treatment Type: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
Table 4.2 Chemotherapy Market by Product Type: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
Table 4.3 Cytarabine Market Forecasts: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
Table 4.4 Daunorubicin Market Forecasts: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
Table 4.5 Other Chemotherapy Products Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
Table 4.6 Targeted Therapy Market by Product Type: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
Table 4.7 Midostaurin Market Forecasts: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
Table 4.8 Enasidenib Market Forecast: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
Table 4.9 Other Targeted Therapy Products Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
Table 5.1 Global Acute Myeloid Leukaemia Market: Revenue ($m), Revenue Share (%) by Region, 2017, 2023, 2028
Table 5.2 Global Acute Myeloid Leukaemia Market by Leading National Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
Table 5.3 US Acute Myeloid Leukaemia Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
Table 5.4 Canada Acute Myeloid Leukaemia Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
Table 5.5 Mexico Acute Myeloid Leukaemia Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
Table 5.6 Europe Acute myeloid leukaemia Market by Country: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
Table 5.7 Germany Acute Myeloid Leukaemia Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
Table 5.8 France Acute Myeloid Leukaemia Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
Table 5.9 United Kingdom Acute Myeloid Leukaemia Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
Table 5.10 Italy Acute Myeloid Leukaemia Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
Table 5.11 Spain Acute Myeloid Leukaemia Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
Table 5.12 Russia Acute Myeloid Leukaemia Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
Table 5.13 Rest for Europe Acute Myeloid Leukaemia Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
Table 5.14 Asia-Pacific Acute myeloid leukaemia Market by Country: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
Table 5.15 Japan Acute Myeloid Leukaemia Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
Table 5.16 China Acute Myeloid Leukaemia Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
Table 5.17 Australia Acute Myeloid Leukaemia Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
Table 5.18 South Korea Acute Myeloid Leukaemia Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
Table 5.19 India Acute myeloid leukaemia Market, Revenue ($m), AGR (%) and CAGR (%) 2017-2028
Table 5.20 Rest of Asia-Pacific Acute Myeloid Leukaemia Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
Table 5.21 LAMEA Acute myeloid leukaemia Market by Country: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
Table 5.22 Brazil Acute Myeloid Leukaemia Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
Table 5.23 Saudi Arabia Acute Myeloid Leukaemia Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
Table 5.24 Republic of South Africa Acute Myeloid Leukaemia Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
Table 5.25 Rest of LAMEA Acute Myeloid Leukaemia Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
Table 6.1 Daiichi Sankyo: Revenue ($m), R&D ($m), 2015-2017
Table 6.2 Daiichi Sankyo Recent Developments
Table 6.3 Celgene: Revenue ($m), R&D ($m), 2015-2017
Table 6.4 Celgene Recent Developments
Table 6.5 TEVA Operating Segments
Table 6.6 TEVA: Revenue ($m), R&D ($m), 2015-2017
Table 6.7 TEVA Recent Developments
Table 6.8 Eisai Operating Segments
Table 6.9 Eisai Revenue ($m), R&D ($m), 2015-2017
Table 6.10 Novartis Operating Segments
Table 6.11 Novartis: Revenue ($m), R&D ($m), 2015-2017
Table 6.12 Novartis Recent Developments
Table 6.13 GSK Operating Segments
Table 6.14 GSK: Revenue ($m), R&D ($m), 2015-2017
Table 6.15 Sunesis: Revenue ($m), R&D ($m), 2015-2017
Table 6.16 Roche Operating Segments
Table 6.17 Roche: Revenue ($m), R&D ($m), 2015-2017
Table 6.18 Roche Recent Developments
Table 6.19 Bristol-Myers: Revenue ($m), 2015-2017
Table 8.1 AML Drugs in the Pipeline: Agent, MOA, Clinical Trial Code
Table 8.2 Completed Clinical Trials for AML
Table 8.3 List of Recruiting Clinical Trials for AML
Table 9.1: Global Acute Myeloid Leukaemia Market by Treatment Type: Revenue ($m), 2017, 2023, 2028
List of Figures
Figure 3.1 Global Acute Myeloid Leukaemia Market: Revenue ($m), 2017-2028
Figure 3.2 Global Acute Myeloid Leukaemia Market Revenue: Market Shares (%), 2017-2028
Figure 4.1 Chemotherapy Market Forecasts: Revenue ($m), 2017-2028
Figure 4.2 Cytarabine Market Forecasts: Revenue ($m), 2017-2028
Figure 4.3 Daunorubicin Market Forecasts: Revenue ($m), 2017-2028
Figure 4.4 Other Chemotherapy Products Market: Revenue ($m), 2017-2028
Figure 4.5 Targeted Therapy Market Forecasts: Revenue ($m), 2017-2028
Figure 4.6 Midostaurin Market Forecasts: Revenue ($m), 2017-2028
Figure 4.7 Enasidenib Market Forecast: Revenue ($m), 2017-2028
Figure 4.8 Other Targeted Therapy Products Market: Revenue ($m), 2017-2028
Figure 5.1 Global Acute Myeloid Leukaemia Market: Revenue ($m) by Leading Nationals, 2017-2028
Figure 5.2 US Acute Myeloid Leukaemia Market: Revenue ($m), 2017-2028
Figure 5.3 Canada Acute Myeloid Leukaemia Market: Revenue ($m), 2017-2028
Figure 5.4 Mexico Acute Myeloid Leukaemia Market: Revenue ($m), 2017-2028
Figure 5.5 Europe Acute Myeloid Leukaemia Market: Revenue ($m), 2017-2028
Figure 5.6 Germany Acute Myeloid Leukaemia Market: Revenue ($m), 2017-2028
Figure 5.7 France Acute Myeloid Leukaemia Market: Revenue ($m), 2017-2028
Figure 5.8 United Kingdom Acute Myeloid Leukaemia Market: Revenue ($m), 2017-2028
Figure 5.9 Italy Acute Myeloid Leukaemia Market: Revenue ($m), 2017-2028
Figure 5.10 Spain Acute myeloid leukaemia Market, Revenue ($m), 2017-2028
Figure 5.11 Russia Acute Myeloid Leukaemia Market: Revenue ($m), 2017-2028
Figure 5.12 Rest of Europe Acute Myeloid Leukaemia Market: Revenue ($m), 2017-2028
Figure 5.13 Asia-Pacific Acute Myeloid Leukaemia Market: Revenue ($m), 2017-2028
Figure 5.14 Japan Acute Myeloid Leukaemia Market: Revenue ($m), 2017-2028
Figure 5.15 China Acute Myeloid Leukaemia Market: Revenue ($m), 2017-2028
Figure 5.16 Australia Acute Myeloid Leukaemia Market: Revenue ($m), 2017-2028
Figure 5.17: South Korea Acute Myeloid Leukaemia Market: Revenue ($m), 2017-2028
Figure 5.18 India Acute Myeloid Leukaemia Market: Revenue ($m), 2017-2028
Figure 5.19 Rest of Asia-Pacific Acute Myeloid Leukaemia Market: Revenue ($m), 2017-2028
Figure 5.20 LAMEA Acute Myeloid Leukaemia Market: Revenue ($m), 2017-2028
Figure 5.21 Brazil Acute Myeloid Leukaemia Market: Revenue ($m), 2017-2028
Figure 5.22 Saudi Arabia Acute Myeloid Leukaemia Market: Revenue ($m), 2017-2028
Figure 5.23 Republic of South Africa Acute Myeloid Leukaemia Market: Revenue ($m), 2017-2028
Figure 5.24 Rest of LAMEA Acute Myeloid Leukaemia Market: Revenue ($m), 2017-2028
Figure 9.1: Global Acute Myeloid Leukaemia Market by Treatment Type: Revenue ($m), 2017, 2023, 2028
AbbVie
Agios Pharmaceuticals, Inc.
Ambit Biosciences Corporation
Amgen
Animas Corporation
Astex
B. Braun Melsungen AG
Baxter, Becton, Dickinson and Company (BD)
Bayer
Boehringer Ingelheim
Bristol-Myers Squibb Company (Bristol-Myers)
Celator Pharmaceuticals, Inc.
Celgene
Clavis Pharma ASA (Clavis Pharma)
Cyclacel
Daiichi Pharmaceutical
Daiichi Sankyo
Eisai Co., Ltd. (Eisai)
F. Hoffmann-La Roche Ltd. (Roche)
Fresenius SE & Co. KGaA
GlaxoSmithKline plc (GSK)
GLOBOCAN
Hospira
Medtronic
Moog Inc.
NeoMed
Norsk Hydro
Novartis
Onyx Pharmaceuticals
Sankyo
Seattle Genetics
Smiths Group Plc.,
Sunesis Pharmaceuticals, Inc. (Sunesis)
TEVA Pharmaceutical Industries Limited (TEVA)
List of Organizations Mentioned in the Report
American Cancer Organization
Baylor Scott and White Research Institute
Benaroya Research Institute at Virginia Mason
Beth Israel Deaconess Medical Center
Breslin Cancer Center
Center for Blood Disorders and Stem Cell Transplantation
Charles A. Sammons Cancer Center
Columbia University Medical
Dana Farber Cancer Institute
Duke Cancer Center
European Commission
Fred Hutchinson Cancer Research Center
Health Canada
Herbert Irving Comprehensive Cancer Center
Institute of Hematology & Blood Diseases Hospital,Tianjin
James Graham Brown Cancer Center
Legacy Emanuel Hospital & Health Center
Mary Babb Randolph Cancer Center
Massachusetts general Hospital
Mayo Clinic
MD Anderson Cancer Center
Medical College of Wisconsin Cancer Center
Medizinische Klinik und Poliklinik I
Memorial Sloan Kettering Cancer Center
Michigan State University
Nantes University Hospital
National Cancer Institute
New Jersey Hematology Oncology Associates
Northwestern University
Ochsner Medical Center
Penn State Hershey Cancer Institute-Clinical Trials Office
Perelman Center for Advanced Medicine
Princess Margaret Hospital
St. Francis Cancer Center
St. Joseph Mercy Hospital
St. Vincent's Comprehensive Cancer Center
Swedish Cancer Institute
The Gayle and Tom Benson Cancer Center
The University of Hong Kong
The University of Iowa
The University of Texas MD Anderson Cancer Center
Thomas Jefferson University
U.S. Food and Drug Administration (FDA)
UCLA Medical Center, Division of Hematology/Oncology
University Hospital, Caen
University of Kansas Cancer Center
University of Kansas Medical Center Research Institute
University of Kentucky
University of Louisville
University of Michigan Health System
University of Pennsylvania
University of Texas M.D. Anderson Cancer Center
VA Caribbean Healthcare System
Weill Cornell Medical College
Weill Medical College of Cornell University
West Virginia University
World Health Organization (WHO)
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
